LLY Sep 2024 420.000 put
| Previous close | 0.4600 |
| Open | 0.5500 |
| Bid | 0.0000 |
| Ask | 0.5900 |
| Strike | 420.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.4300 - 0.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 71 |
- Reuters
UPDATE 2-US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss its experimental Alzheimer's disease drug, donanemab, on June 10. Donanemab has faced two separate regulatory delays in the United States, while a similar therapy by Eisai and partner Biogen, called Leqembi, received the U.S. Food and Drug Administration's approval last year. Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its approval.
Investor's Business DailyMutual Funds Can't Get Enough Amazon, Broadcom
Amazon stock climbs back near highs and is a mutual funds favorite. Shares gained more than 23% this year. Broadcom stock tests a key level.
Simply Wall St.Eli Lilly First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Eli Lilly ( NYSE:LLY ) First Quarter 2024 Results Key Financial Results Revenue: US$8.77b (up 26% from 1Q 2023). Net...
